Oh Hyunwoo, Yoon Eileen L, Jun Dae Won, Ahn Sang Bong, Lee Hyo-Young, Jeong Jae Yoon, Kim Hyoung Su, Jeong Soung Won, Kim Sung Eun, Shim Jae-Jun, Sohn Joo Hyun, Cho Yong Kyun
Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea.
Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea.
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2793-2802.e6. doi: 10.1016/j.cgh.2020.02.046. Epub 2020 Mar 2.
BACKGROUND & AIMS: Studies to evaluate risks of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection treated with the nucelos(t)ide analogues entecavir or tenofovir have produced contradictory results. These differences are likely to be the result of censored data, insufficient observation periods, and different observation periods for patients treated with different drugs. We aimed to compare the incidence of HCC development between patients treated with oral entecavir or tenofovir and followed up for the same time periods.
We performed a retrospective study, collecting data from 1560 treatment-naive patients with chronic HBV infection who were first treated with entecavir (n = 753) or tenofovir (n = 807) from 2011 through 2015 at 9 academic hospitals in Korea. Clinical outcomes were recorded over a mean time period of 4.7 ± 1.0 years, from 92.4% of patients treated with tenofovir and 92.7% of patients treated with entecavir.
Thirty-four patients in the entecavir group (4.5%) and 45 patients in the tenofovir group (5.6%) developed HCC during the follow-up period. The incidence of HCC did not differ significantly between groups, even in a 516-pair propensity score-matched population.
In a retrospective study of 1560 treatment-naive patients with chronic HBV infection, the incidence of HCC did not differ significantly between patients treated with entecavir vs tenofovir over the same observation period.
KCT0003487.
评估接受核苷（酸）类似物恩替卡韦或替诺福韦治疗的慢性乙型肝炎病毒（HBV）感染患者发生肝细胞癌（HCC）风险的研究结果相互矛盾。这些差异可能是由于删失数据、观察期不足以及不同药物治疗患者的观察期不同所致。我们旨在比较接受口服恩替卡韦或替诺福韦治疗并随访相同时间段的患者中HCC发生的发生率。
我们进行了一项回顾性研究，收集了2011年至2015年期间在韩国9家学术医院首次接受恩替卡韦（n = 753）或替诺福韦（n = 807）治疗的1560例初治慢性HBV感染患者的数据。在平均4.7±1.0年的时间段内记录临床结局，替诺福韦治疗患者的记录比例为92.4%，恩替卡韦治疗患者的记录比例为92.7%。
在随访期间，恩替卡韦组有34例患者（4.5%）发生HCC，替诺福韦组有45例患者（5.6%）发生HCC。两组之间HCC的发生率无显著差异，即使在516对倾向评分匹配的人群中也是如此。
在一项对1560例初治慢性HBV感染患者的回顾性研究中，在相同观察期内，接受恩替卡韦与替诺福韦治疗的患者中HCC的发生率无显著差异。
KCT0003487。
